209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein

✍ Scribed by P. Schöffski; I. Breidenbach; O. Bolte; M. Stadler; S. Zilz; K. Wilhelm-Ogunbiyi; H. Lentzen

• Book ID: 118621392
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 294 KB
• Volume: 2
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(04)80217-9